Clinical Trial: NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | C. Babis Andreadis |
| Information Provided By: | University of California, San Francisco |
| Last Update Posted: | 2026-10-26 |
Study Overview
Brief Summary
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).
Official Title
A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions
Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma, Non-Hodgkin Lymphoma
Intervention / Treatment
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Biological: anti-CD19 CAR-T cells
Other Study ID Numbers
- 19703
- NCI-2020-06711
Start Date (Actual)
2020-09-11
Primary Completion Date (Estimated)
2026-10-31
Study Completion Date (Estimated)
2026-10-31
Enrollment (Estimated)
36
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | C. Babis Andreadis |
| Information Provided By: | University of California, San Francisco |
| Last Update Posted: | 2026-10-26 |
Study Overview
Brief Summary
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).
Official Title
A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions
Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma, Non-Hodgkin Lymphoma
Intervention / Treatment
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Biological: anti-CD19 CAR-T cells
Other Study ID Numbers
- 19703
- NCI-2020-06711
Start Date (Actual)
2020-09-11
Primary Completion Date (Estimated)
2026-10-31
Study Completion Date (Estimated)
2026-10-31
Enrollment (Estimated)
36
Study Type
Interventional
Phase
Phase 1